Related Experiment Video
Updated: May 12, 2026

Antibiotic Dereplication Using the Antibiotic Resistance Platform
Published on: October 17, 2019
Is the GAIN Act a turning point in new antibiotic discovery?
1Department of Biochemistry and Biomedical Sciences, and the Michael G. DeGroote Institute for Infectious Disease Research, McMaster University, 1280 Main Street West, Hamilton, ON L8S 4K1, Canada. ebrown@mcmaster.ca
Abstract:
The United States GAIN (Generating Antibiotic Incentives Now) Act is a call to action for new antibiotic discovery and development that arises from a ground swell of concern over declining activity in this therapeutic area in the pharmaceutical sector. The GAIN Act aims to provide economic incentives for antibiotic drug discovery in the form of market exclusivity and accelerated drug approval processes. The legislation comes on the heels of nearly two decades of failure using the tools of modern drug discovery to find new antibiotic drugs. The lessons of failure are examined herein as are the prospects for a renewed effort in antibiotic drug discovery and development stimulated by new investments in both the public and private sector.
Related Concept Videos
Antibiotic Selection
Development of Antibiotic Resistance
Inhibitors of Bacterial Protein Synthesis
Clinical Significance of Antibiotic Resistance
Mechanism of Antibiotic Resistance in MRSA
Production of Antibiotics

